Evidence map›Paper›PMID 42347511›Full record

ArticleToxins2026

Recombinant Human Fab Antibodies Differentially Neutralize Shiga Toxin in Renal Epithelial and Endothelial Cells.

Fernando D Gómez, Daniela Luz, Isabel Chinen, Daniel Girón, Raissa L Ferreira, Camila Henrique, Ariela O P Bom, Izabella M Henrique, Wanderson Marques da Silva, Flavia Sacerdoti and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Fernando D GómezUniversidad de Buenos Aires, Facultad de Ciencias Médicas, Departamento de Ciencias Fisiológicas, Laboratorio de Fisiopatogenia, Buenos Aires C1121 ABG, Argentina.
Daniela LuzLaboratório de Bacteriologia, Instituto Butantan, São Paulo, SP 05503-900, Brazil.
Isabel ChinenInfectious Hazard Management Unit, Public Health Department, Pan American Health Organization, Washington DC 20037, USA.
Daniel GirónUniversidad de Buenos Aires, Facultad de Ciencias Médicas, Departamento de Ciencias Fisiológicas, Laboratorio de Fisiopatogenia, Buenos Aires C1121 ABG, Argentina.ORCID 0009-0007-1009-314X
Raissa L FerreiraLaboratório de Bacteriologia, Instituto Butantan, São Paulo, SP 05503-900, Brazil.
Camila HenriqueLaboratório de Bacteriologia, Instituto Butantan, São Paulo, SP 05503-900, Brazil.ORCID 0000-0001-6727-2850
Ariela O P BomLaboratório de Bacteriologia, Instituto Butantan, São Paulo, SP 05503-900, Brazil.
Izabella M HenriqueLaboratório de Bacteriologia, Instituto Butantan, São Paulo, SP 05503-900, Brazil.
Wanderson Marques da SilvaUniversidad de Buenos Aires, Facultad de Ciencias Médicas, Departamento de Ciencias Fisiológicas, Laboratorio de Fisiopatogenia, Buenos Aires C1121 ABG, Argentina.
Flavia SacerdotiUniversidad de Buenos Aires, Facultad de Ciencias Médicas, Departamento de Ciencias Fisiológicas, Laboratorio de Fisiopatogenia, Buenos Aires C1121 ABG, Argentina.
Elizabeth S MiliwebskyServicio Fisiopatogenia, Departamento Bacteriología, Instituto Nacional de Enfermedades Infecciosas ANLIS "Dr. Carlos G. Malbrán", Buenos Aires C1282 AFF, Argentina.ORCID 0000-0002-3198-4175
Gang ChenTerrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON M5S 2Z9, Canada.
Claudia C CarbonariServicio Fisiopatogenia, Departamento Bacteriología, Instituto Nacional de Enfermedades Infecciosas ANLIS "Dr. Carlos G. Malbrán", Buenos Aires C1282 AFF, Argentina.ORCID 0000-0002-5312-4555
Sachdev S SidhuTerrence Donnelly Centre for Cellular and Biomolecular Research, University of Toronto, Toronto, ON M5S 2Z9, Canada.
Roxane M F PiazzaLaboratório de Bacteriologia, Instituto Butantan, São Paulo, SP 05503-900, Brazil.ORCID 0000-0003-0068-8506
María Marta AmaralUniversidad de Buenos Aires, Facultad de Ciencias Médicas, Departamento de Ciencias Fisiológicas, Laboratorio de Fisiopatogenia, Buenos Aires C1121 ABG, Argentina.

Funding

FAPESP Postdoctoral Fellowship 2017/17006-2FAPESP Research Internship Abroad (BEPE) Fellowship 2015/07153-2São Paulo Research Foundation 2022/06099-8, 2018/13895-0, and 2015/17117-8
6 · The paper itself

Abstract

Hemolytic Uremic Syndrome (HUS) is a severe clinical manifestation primarily triggered by Shiga toxin-producing

Indexed as

Antibodies, NeutralizingEndothelial CellsEpithelial CellsImmunoglobulin Fab FragmentsShiga ToxinShiga Toxin 1AnimalsCell LineChlorocebus aethiopsHemolytic-Uremic SyndromeHumansRecombinant ProteinsShiga-Toxigenic Escherichia coliVero CellsAntibodies, NeutralizingImmunoglobulin Fab FragmentsRecombinant ProteinsShiga ToxinShiga Toxin 1Fabshemolytic uremic syndromeShiga toxinSTECtoxin neutralization

Identifiers

PMID42347511
PMCPMC13307652

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.